Ali Ataya, MD - Research

Research at a glance

Top areas of exploration

Dyspnea , 14 publications
Hypertension, Pulmonary , 6 publications
Pulmonary Alveolar Proteinosis , 5 publications
Lung , 5 publications

Research activity

116 publications

405 citations

Why is this important?

Active clinical trials

IMPALA-2

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive鈥�

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

ROR-PH-303 (APD811-303)

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

United therapeutics 301

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO)鈥�

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

My publications

116 publications

2024

A perfectly imperfect engine: Utilizing the digital twin paradigm in pulmonary hypertension

Pulmonary Circulation

鈥�

2024

Abdominal pain in a patient with epistaxis, telangiectasias, and arteriovenous malformations.

Cleveland Clinic journal of medicine

鈥�

2024

Autoimmune Pulmonary Alveolar Proteinosis: A Review of Pathogenesis and Emerging Therapies

Current Pulmonology Reports

2024

Comment on the European Respiratory Society pulmonary alveolar proteinosis guidelines.

The European respiratory journal

鈥�

2024

Diffuse hyperdense micronodular airspace opacities in pulmonary alveolar microlithiasis

Thorax

BOB体育